Secondly, the benefit of adjuvant chemotherapy is observed in patients with p53mut endometrial cancer,34 whilst the de-escalation of therapy in patients with POLE mutated (POLEmut) endometrial cancer, which has a favourable outcome, is being investigated. Here, POLE is linked to endometrial cancer.